An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
Launched by M.D. ANDERSON CANCER CENTER · Mar 9, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new type of imaging scan called intravoxel incoherent motion diffusion weighted imaging (IVIM DWI) to help doctors understand how well treatments are working for patients with colorectal cancer that has spread to the liver. The goal is to see if this advanced scan can measure changes in the cancer before and after patients receive chemotherapy. This could help doctors better assess treatment responses and improve care for patients with liver metastases from colorectal cancer.
To participate in this trial, patients must have at least one liver metastasis (cancer that has spread to the liver) that is at least 1 cm in size and be starting new chemotherapy treatment. They should not have received any chemotherapy or other treatments for their liver cancer before joining the study. Participants will have follow-up appointments at MD Anderson, where they will undergo the new imaging scans before and after their surgery. This trial is currently recruiting patients of all genders, aged 65 to 74. It’s important to note that individuals with certain medical conditions, like allergies to gadolinium or those with pacemakers, are not eligible to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with treatment-naive resectable CLM, who will start chemotherapy with oxaliplatin with fluorouracil (5-FU)/leucovorin (FOLFOX), irinotecan with 5-FU/leucovorin (FOLFIRI), or a combination, such as fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), with or without a biologic agent
- • Patients with at least 1 colorectal liver metastasis measuring at least 1 cm
- • Patients with anticipated follow-up before and after surgery at MD Anderson
- Exclusion Criteria:
- • Patients who have already received preoperative chemotherapy for the CLM or will undergo radiation therapy, ablative therapies, or other non-surgical therapies directed at the liver
- • Patients allergic to gadolinium
- • Patients with pacemakers
- • Greater than 400 pounds in weight
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Priya R Bhosale
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials